Summary & Overview
CPT 91321: SARS–CoV–2 Vaccine, 25 mcg Intramuscular Injection
Headline: New CPT code 91321 denotes a 25 mcg intramuscular SARS–CoV–2 vaccine product and clarifies national billing for routine COVID–19 immunization.
Lead: CPT code 91321 identifies a SARS–CoV–2 vaccine product formulated as 25 mcg/0.25 mL delivered by intramuscular injection to reduce the risk of COVID–19. This code standardizes reporting for vaccine supply and supports consistent coverage determinations across major payers.
Why it matters: Accurate use of CPT code 91321 matters nationally because it ensures clear communication about vaccine products in claims, supports vaccine inventory and public-health tracking, and informs payer coverage and payment policies. It affects immunization program operations across outpatient sites where intramuscular COVID–19 vaccines are delivered.
Payers in scope: Analysis covers major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
What readers will learn: The publication explains the clinical product represented by CPT code 91321, typical service settings for administration, common billing considerations, and where to find policy updates and benchmarks. It summarizes payer coverage context and identifies gaps where data were not provided. Data not available in the input are noted where applicable.
Billing Code Overview
CPT code 91321 represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 25 mcg/0.25 mL.
Service Type: Vaccine administration — intramuscular SARS–CoV–2 immunization
Typical Site of Service: Ambulatory clinic, physician office, pharmacy-based immunization clinic, or other outpatient vaccination setting
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or adolescent presenting for routine immunization or COVID-19 booster in an outpatient clinic, primary care office, pharmacy vaccination clinic, or public health clinic. The vaccine 91321 (SARS–CoV–2 vaccine, 25 mcg/0.25 mL, intramuscular) is prepared by qualified staff and administered via intramuscular injection, usually into the deltoid muscle. Workflow steps include verification of patient identity and eligibility, review of immunization history and contraindications, informed consent and counseling on common side effects, screening for acute illness or fever, administration of the vaccine, documentation of lot number and injection site, observation for immediate adverse reaction (typically 15 minutes, 30 minutes for higher risk patients), and entry of the immunization into the medical record and any jurisdictional immunization registry. Typical sites of service are outpatient clinic, physician office, pharmacy, community vaccination site, and public health clinic. Common clinical scenarios include primary series completion, dose-sparing or age-specific dosing per product labeling, and booster administration for waning immunity or variant-specific updates.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Use when no specific modifier applies and standard billing is submitted |